Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol

Published:2018-04-26 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Syn Nicholas LX¹,Roudi Raheleh²,Wang Louis Zizhao³,Wang Lingzhi⁴,Loh Marie⁵,Huang Yiqing¹,Ou Sai-Hong Ignatius⁶,Soong Richie⁷,Drilon Alexander⁸,Wee Ian¹

Affiliation:

1. National University Cancer Institute; Department of Haematology-Oncology; 1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore Singapore 119228

2. Iran University of Medical Sciences; Oncopathology Research Center; Hemmat Street, Next to Milad Tower Teheran Iran 14496-14530

3. National University of Singapore; Yong Loo Lin School of Medicine; Singapore Singapore

4. Cancer Science Institute of Singapore; Singapore Singapore

5. Agency for Science, Technology and Research; Translational Laboratory in Genetic Medicine; 8A Biomedical Grove, Immunos Level 5 Singapore Singapore 138648

6. Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center; Division of Hematology-Oncology; 101 city drive, Bldg 56, RT81, Rm 241, Orange County Irvine USA CA 92868-3298

7. National University of Singapore; Department of Pathology; 14 Medical Drive, #12-01 Singapore Singapore 117599

8. Memorial Sloan-Kettering Cancer Center; Early Drug Development Service; 1275 York Avenue New York USA NY 10065

Publisher

Wiley

Subject

Pharmacology (medical)

Reference81 articles.

1. American Cancer Society Global Cancer Facts & Figures. 3rd Edition www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf 1 61

2. Edge SB Byrd DR Compton CC Fritz AG Greene FL Trotti A editor(s) AJCC Cancer Staging Manual, 7th edition www.cancerstaging.org/references-tools/deskreferences/Documents/AJCC%207th%20Ed%20Cancer%20Staging%20Manual.pdf

3. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study;Antonia;Lancet Oncology,2016

4. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis;Ardizzoni;Journal of the National Cancer Institute,2007

5. A review of human carcinogens - Part F: chemical agents and related occupations;Baan;Lancet Oncology,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers;Cancers;2024-02-07

2. Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non-small cell lung cancer: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2022-04-08

3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2021-04-30

4. Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas;Frontiers in Oncology;2021-03-05

5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2020-12-14